QCG
FENC icon

Quadrant Capital Group’s Fennec Pharmaceuticals FENC Stock Holding History

Quadrant Capital Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-79
Closed – – 2451
2021
Q1 		$0 Hold
79
– – ﹤0.01% 2403
2020
Q4 		$1K Buy
+79
New +$602 ﹤0.01% 2099

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Quadrant Capital Group's FENC Position: Q2 2021 in Review

Quadrant Capital Group sold out of Fennec Pharmaceuticals (FENC) in Q2 2021, closing a stake of 79 shares.

Quadrant Capital Group first reported a position in FENC in Q4 2020 and held it in 2 quarters. The position peaked at $1K in Q4 2020. 39 funds tracked by Wall St. Rank hold FENC as of Q2 2021.

  • Quadrant Capital Group reported no remaining Fennec Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 79 Fennec Pharmaceuticals shares in Q2 2021.
  • Quadrant Capital Group first reported a position in Fennec Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Quadrant Capital Group's Fennec Pharmaceuticals position peaked at $1K in Q4 2020.
  • 39 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2021.

Based on Quadrant Capital Group's 13F filing for Q2 2021, filed 9 Aug 2021.